Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New strategy sees Genmab land antibody research deal with Seattle Genetics

This article was originally published in Scrip

Executive Summary

Genmab's recently appointed CEO Professor Jan van de Winkel has wasted little time in stamping his authority on the struggling Danish biotech, announcing a new corporate strategy to reduce operating costs by 20% next year and signing a research deal with Seattle Genetics.

You may also be interested in...



Seattle Buys Into Future of Genmab ADC Deal

In a six-year-old collaboration with Genmab, Seattle Genetics has decided to exercise its option to co-develop and co-commercialize tisotumab vedotin, an antibody-drug conjugate for solid tumors, granting both companies a 50:50 share.

Myotec and Hybrid merge to form PsiOxus

Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.

Trophos's MitoCare programme receives €6 million EU funding

A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC010169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel